Table 3.
Apparent violations of class I recommendations for rhythm control therapy use in the EAST-AFNET 4 population
| Randomized group |
||||
|---|---|---|---|---|
| Early rhythm control (N = 1395) | Usual care (N = 1394) | Total (N = 2789) | P-value | |
| Severe coronary artery disease in patients receiving flecainide or propafenone at discharge | 32 (2.3%) | 3 (0.2%) | 35 (1.3%) | <0.001a |
| Reduced left ventricular function in patients receiving flecainide or propafenone at discharge | 2 (0.1%) | 1 (0.1%) | 3 (0.1%) | 0.572a |
| Reduced left ventricular function in patients receiving dronedarone at discharge | 3 (0.2%) | 0 (0.0%) | 3 (0.1%) | 0.250b |
| At least one violation of guideline conform use | 37 (2.7%) | 4 (0.3%) | 41 (1.5%) | <0.001a |
Over 97% of patients received rhythm control therapy in line with recommendations of the ESC guidelines published between 2012 and 2020.1,10,11 The most common apparent violation was the use of sodium channel blockers in patients with coronary artery disease (35 patients, 1.3%).
a
P-value resulting from mixed logistic regression with centre as random effect.
b
P-value resulting from Fisher’s exact test.